Yan-Nan Wang

Increased mitochondrial biogenesis by GPR56 contributes to venetoclax resistance in acute myeloid leukemia

Acute myeloid leukemia is a highly heterogeneous hematologic malignancy with an extremely poor prognosis. Although the BCL-2 inhibitor venetoclax introduced a new therapeutic option for patients, its widespread resistance substantially limited clinical application, and the underlying molecular mechanisms remained inc...